The ongoing pandemic will not affect AstraZeneca’s performance in 2020, the company has said after its first quarter results beat analysts’ expectations.
Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.